Literature DB >> 21527561

Inclusion of patients with brain metastases in phase I trials: an unmet need.

Mrinal M Gounder1, David R Spriggs.   

Abstract

Patients with brain metastases are increasing in number; however, these patients are often excluded in phase I/II trials due to perceived poor prognosis, risk of hemorrhage, inefficient drug delivery, and confounding toxicities. Tsimberidou and colleagues demonstrate that selected patients can be appropriately enrolled in phase I trials and have outcomes representative of the general cancer population. ©2011 AACR.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21527561     DOI： 10.1158/1078-0432.CCR-11-0759

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Authors:  Mrinal M Gounder; Lakshmi Nayak; Solmaz Sahebjam; Alona Muzikansky; Armando J Sanchez; Serena Desideri; Xiaobu Ye; S Percy Ivy; L Burt Nabors; Michael Prados; Stuart Grossman; Lisa M DeAngelis; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

2.  Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?

Authors:  Emil Lou; Paul W Sperduto
Journal:  Ann Transl Med       Date:  2016-01

Review 3.  Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Authors:  R Costa; B A Carneiro; D A Wainwright; C A Santa-Maria; P Kumthekar; Y K Chae; W J Gradishar; M Cristofanilli; F J Giles
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 51.769

Review 4.  Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.

Authors:  Nuria Kotecki; Florence Lefranc; Daniel Devriendt; Ahmad Awada
Journal:  Ther Adv Med Oncol       Date:  2018-06-22       Impact factor: 8.168

5.  Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience.

Authors:  Sonya Chew; Hailey Kathryn Carroll; Waseem Darwish; Oleksandr Boychak; Michaela Higgins; John McCaffrey; Catherine Margaret Kelly
Journal:  Cancer Manag Res       Date:  2021-11-02       Impact factor: 3.989

6.  Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Authors:  Niamh Coleman; Vasiliki Michalarea; Scheryll Alken; Karim Rihawi; Raquel Perez Lopez; Nina Tunariu; Ann Petruckevitch; L R Molife; Udai Banerji; Johann S De Bono; Liam Welsh; Frank Saran; Juanita Lopez
Journal:  J Neurooncol       Date:  2018-04-10       Impact factor: 4.130

7.  Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis.

Authors:  Nehal Gupta; Sanjay K Srivastava
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-28

Review 8.  Dabrafenib and its potential for the treatment of metastatic melanoma.

Authors:  Alexander M Menzies; Georgina V Long; Rajmohan Murali
Journal:  Drug Des Devel Ther       Date:  2012-12-11       Impact factor: 4.162
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.